CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA

CARsgen Presents Updated Research Results on BCMA CAR T-cell Product (CT053) at 2021 ASH Annual Meeting

CARsgen Announces CAR T-cell Product Candidate CT041 Granted PRIME Eligibility by the EMA

Appealing Data of CARsgen Therapeutics' CAR-T (CT041) in Advanced Gastric Cancer Presented at ESMO

CARsgen Expanded Collaboration with Shanghai Cancer Institute to Enhance Scientific and Technological Transformation

CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR T cells for the Treatment of Gastric and Gastroesophageal Junction Cancers

CARsgen Therapeutics Receives IND Clearance from the NMPA for CT041 CLDN18.2-CAR T cells

CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR T cells (CT053) for the Treatment of Multiple Myeloma

CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs

CARsgen Therapeutics Receives IND Clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody